Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 2.46
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA, overpriced on P/FC.
Data is available to registered users only
Buy
Sell